Close

Cyclacel Pharma (CYCC) Achieves Key Business Objectives in First Half of 2022 and Continues to Advance Clinical Pipeline

Go back to Cyclacel Pharma (CYCC) Achieves Key Business Objectives in First Half of 2022 and Continues to Advance Clinical Pipeline

Cyclacel Pharmaceuticals Achieves Key Business Objectives in First Half of 2022 and Continues to Advance Clinical Pipeline

June 30, 2022 9:15 AM EDT

- Completed Enrollment in Phase 1 Dose Escalation with Oral Fadraciclib in Solid Tumors -

- No Dose Limiting Toxicities Observed at All Dose Levels Enrolled to Date -

- Demonstrated Evidence of Target Engagement for CDK2 and CDK9 -

- Early Anticancer Activity, Including Partial Response and Stable Disease with Tumor Shrinkage,Observed in Patients with Endometrial Cancer, Pancreatic Cancer and T Cell Lymphoma -

- R&D Day Planned for Fall 2022 -

BERKELEY HEIGHTS, N.J., June 30, 2022... More